Madrigal Pharmaceuticals, Inc. (MDGL) financial statements (2021 and earlier)

Company profile

Business Address 200 BARR HARBOR DRIVE, SUITE 400
WEST CONSHOHOCKEN, PA 19428
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:284439484192406798
Cash and cash equivalents544757149193546
Short-term investments23039242643213252
Other undisclosed cash, cash equivalents, and short-term investments     00
Other undisclosed current assets1110112
Total current assets:285440485192416899
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment1100001
Other noncurrent assets      0
Total noncurrent assets:2200001
TOTAL ASSETS:2874424851924168101
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4625810569
Accounts payable1122113
Accrued liabilities452468422
Employee-related liabilities     34
Debt 0   59
Other undisclosed current liabilities0    712
Total current liabilities:472581051831
Noncurrent Liabilities
Long-term debt and lease obligation00    5
Long-term debt, excluding current maturities      5
Capital lease obligations    0
Operating lease, liability00
Other undisclosed noncurrent liabilities(0)      
Total noncurrent liabilities:00    5
Total liabilities:472581051836
Stockholders' equity
Stockholders' equity attributable to parent240417477182365065
Common stock0000000
Additional paid in capital665640617289112757703
Accumulated other comprehensive income (loss)00(0)(0)000
Accumulated deficit(425)(223)(139)(106)(75)(706)(638)
Total stockholders' equity:240417477182365065
TOTAL LIABILITIES AND EQUITY:2874424851924168101

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:0 00   
Operating expenses(207)(95)(41)(32)(25)(68)(84)
Other undisclosed operating loss(0) (0)(0)   
Operating loss:(207)(95)(41)(32)(25)(68)(84)
Interest and debt expense    (1)  
Loss before gain (loss) on sale of properties:(207)(95)(41)(32)(26)(68)(84)
Other undisclosed net income41181   
Net loss attributable to parent:(202)(84)(33)(31)(26)(68)(84)
Other undisclosed net income (loss) available to common stockholders, basic    0(1)(2)
Net loss available to common stockholders, diluted:(202)(84)(33)(31)(26)(69)(86)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(202)(84)(33)(31)(26)(68)(84)
Comprehensive loss:(202)(84)(33)(31)(26)(68)(84)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)1(0)(0)0(1)(2)
Comprehensive loss, net of tax, attributable to parent:(202)(83)(33)(31)(26)(69)(86)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: